Evidence map›Paper›PMID 36776644›Full record

ArticleCrohn's & colitis 3602021

Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug Monitoring.

Amy Hemperly, Marla C Dubinsky, Andres Yarur, Anita Afzali, Stephen Hanauer, Subra Kugathasan, Millie D Long, Shervin Rabizadeh, Robbyn Sockolow, Lauren Okada and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Crohn's & colitis 360, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Amy HemperlyDepartment of Pediatrics, Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0001-9841-222X
Marla C DubinskyDivision of Pediatric Gastroenterology and Nutrition, Icahn School of Medicine, New York, New York, USA.
Andres YarurDivision of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Anita AfzaliDivision of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Stephen HanauerDivision of Gastroenterology and Hepatology, Northwestern University-Feinberg School of Medicine, Chicago, Illinois, USA.
Subra KugathasanDivision of Pediatric Gastroenterology, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-7337-2257
Millie D LongDepartment of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Shervin RabizadehDepartment of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Robbyn SockolowDepartment of Pediatrics, Division of Gastroenterology and Nutrition, Weill Cornell Medicine, New York, New York, USA.
Lauren OkadaPrometheus Biosciences, San Diego, California, USA.
Anjali JainPrometheus Biosciences, San Diego, California, USA.
Maria T AbreuDepartment of Medicine, Division of Gastroenterology, Crohn's & Colitis Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
Niels Vande CasteeleDepartment of Medicine, University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0003-0854-0274

Funding

San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8M
NIDDK NIH HHS P30 DK120515
6 · The paper itself

Abstract

Background and Aims: Therapeutic drug monitoring (TDM) with measurement of serum drug and antidrug antibody concentrations is used to optimize tumor necrosis factor antagonists (anti-TNF). The endoscopic healing index (EHI) is a validated serum-based assay to measure mucosal inflammation in adults with Crohn disease (CD). Our objectives were to evaluate the relationship between EHI and TDM results and to determine the anti-TNF concentration range associated with EHI <20 (consistent with endoscopic remission). Methods: Adult and pediatric patients with CD (N = 1731) were selected retrospectively from a clinical laboratory cohort. Patients were selected if they had an ICD-10 code for CD and if results for EHI and TDM were available within 30 days of each other. The relationship between EHI and TDM results was examined and the anti-TNF concentration range associated with EHI <20 vs >50 was evaluated. Results: Median anti-TNF concentration was higher in patients with EHI <20 vs >50 for infliximab (N = 796): 11.1 vs 3.4 µg/mL and for adalimumab (N = 935): 9.2 vs 5.0 µg/mL ( Conclusions: We report the anti-TNF concentration range associated with EHI <20. Combined testing of EHI and TDM is proposed as a noninvasive approach for treat-to-target management which could improve the ability to monitor disease and optimize anti-TNF therapy.

Indexed as

biomarkerendoscopic remissioninflammatory bowel diseasetreat-to-target

Identifiers

PMID36776644
PMCPMC9802228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.